These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 20860621

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.
    Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 19. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
    Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H.
    Cancer Chemother Pharmacol; 2016 Feb 01; 77(2):281-8. PubMed ID: 26791871
    [Abstract] [Full Text] [Related]

  • 20. The use of the Calvert formula to determine the optimal carboplatin dosage.
    van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH.
    J Cancer Res Clin Oncol; 1995 Feb 01; 121(8):478-86. PubMed ID: 7642691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.